DNMT3A and diffuse large B-cell lymphoma: We then studied the correlation between DNMT3A protein overexpression (defined as ≥42% of DNMT3A-positive tumor cells) or DOT1L protein expression (defined as > 1% of DOT1L-positive tumor cells) and the usual clinicopathological parameters (gender, age, Ann-Arbor clinical stage, lactate dehydrogenase serum level, performance status and the IPI score) in the 31 patients with DLBCL.